前列腺素类似物和前列腺酰胺对中央角膜厚度的影响。
The effect of prostaglandin analogs and prostamide on central corneal thickness.
作者信息
Hatanaka Marcelo, Vessani Roberto M, Elias Isalina R, Morita Celso, Susanna Remo
机构信息
Department of Opthalmology, University of São Paulo School of Medicine, São Paulo, Brazil.
出版信息
J Ocul Pharmacol Ther. 2009 Feb;25(1):51-3. doi: 10.1089/jop.2007.0125.
OBJECTIVE
The aim of this study was to verify the influence of prostaglandin analogs and prostamide on central corneal thickness (CCT).
METHODS
A prospective analysis was done of CCT in glautomatous patients submitted to monotherapy with prostaglandin analogs (latanoprost 0.005% or travoprost 0.004%) or prostamide (bimatoprost 0.03%) during an 8-week period. A control group of patients without any ocular medication was also evaluated. CCT measurements were performed with a commercially available ultrasound pachymeter. A total of 73 patients were included in this study. Mean age was 68.5 +/- 9.2 (range, 48-85) years old.
RESULTS
A statistically significant reduction in CCT was observed in all groups, except the control group (n = 21): Bimatoprost 0.03% group (n = 21): 544.41 +/- 35.4 vs. 540.35 +/- 35.9 microm (P = 0.039); travoprost 0.004% group (n = 17): 538.47 +/- 32.0 vs. 532.25 +/- 30.4 microm (P = 0.009); latanoprost 0.005% group (n = 14): 548.57 +/- 32.4 vs. 543.88 +/- 35.6 microm (P = 0.036).
CONCLUSION
Topical therapy with prostaglandin analogs and bimatoprost is associated with CCT reduction over a period of at least 8 weeks.
目的
本研究旨在验证前列腺素类似物和前列腺酰胺对中央角膜厚度（CCT）的影响。
方法
对接受前列腺素类似物（0.005%拉坦前列素或0.004%曲伏前列素）或前列腺酰胺（0.03%比马前列素）单药治疗8周的青光眼患者的CCT进行前瞻性分析。还评估了未使用任何眼部药物的对照组患者。使用市售超声角膜测厚仪进行CCT测量。本研究共纳入73例患者。平均年龄为68.5±9.2（范围48 - 85）岁。
结果
除对照组（n = 21）外，所有组的CCT均出现统计学显著降低：0.03%比马前列素组（n = 21）：544.41±35.4对540.35±35.9微米（P = 0.039）；0.004%曲伏前列素组（n = 17）：538.47±32.0对532.25±30.4微米（P = 0.009）；0.005%拉坦前列素组（n = 14）：548.57±32.4对543.88±35.6微米（P = 0.036）。
结论
前列腺素类似物和比马前列素局部治疗至少8周与CCT降低有关。
Zotero 插件